Mark A. Gill
Impact in
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
-
- Antibiotic Use and Resistance
Papers in
- Pharmacology 31
- Antibiotics Pharmacokinetics and Efficacy 30
-
- Pharmaceutical studies and practices 9
- Co-authors
- Stan G. Louie (10 shared papers)Mark P. Okamoto (9 shared papers)Alfred Chin (18 shared papers)Paul M. Beringer (8 shared papers)Bradley R. Williams (1 shared paper)Jack W. Kern (7 shared papers)Albert E. Yellin (12 shared papers)David A. Sclar (6 shared papers)
- Journals
- American Journal of Health-System Pharmacy (22 papers)Therapeutic Drug Monitoring (9 papers)Antimicrobial Agents and Chemotherapy (4 papers)Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (3 papers)Annals of Pharmacotherapy (2 papers)
- Partner nations
- United StatesJapanNorway
In The Last Decade
Mark A. Gill
59 papers receiving 925 citations
Peers
Comparison fields: 5 of 118
- Molecular Medicine 130
- Applied Microbiology and Biotechnology 46
- Pharmacology 352
- Family Practice 16
- Geriatrics and Gerontology 28
Countries citing papers authored by Mark A. Gill
This map shows the geographic impact of Mark A. Gill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Gill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Gill more than expected).
Fields of papers citing papers by Mark A. Gill
This network shows the impact of papers produced by Mark A. Gill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Gill. The network helps show where Mark A. Gill may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark A. Gill, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2000 | 99 | |
| 2 | 2003 | 96 | |
| 3 | 2001 | 50 | |
| 4 | 1992 | 49 | |
| 5 | 2005 | 48 | |
| 6 | 1994 | 48 | |
| 7 | 2005 | 43 | |
| 8 | 2004 | 38 | |
| 9 | 1979 | 35 | |
| 10 | 1991 | 35 | |
| 11 | 2003 | 33 | |
| 12 | 1987 | 32 | |
| 13 | 1983 | 27 | |
| 14 | 2002 | 24 | |
| 15 | 2002 | 21 | |
| 16 | 1991 | 20 | |
| 17 | 2008 | 16 | |
| 18 | 2004 | 16 | |
| 19 | 1992 | 15 | |
| 20 | 1986 | 15 |
About Mark A. Gill
Mark A. Gill is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health, Pulmonary and Respiratory Medicine, Molecular Medicine and Emergency Medicine, having authored 60 papers that have together received 993 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (30 papers), Pharmaceutical studies and practices (9 papers), Antibiotic Resistance in Bacteria (7 papers), Pneumonia and Respiratory Infections (6 papers), Appendicitis Diagnosis and Management (6 papers), Cystic Fibrosis Research Advances (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Antibiotic Use and Resistance (4 papers). The work is most often cited by research in Molecular Medicine (130 citations), Applied Microbiology and Biotechnology (46 citations), Pharmacology (352 citations), Family Practice (16 citations) and Geriatrics and Gerontology (28 citations). Mark A. Gill has collaborated with scholars based in United States, Japan and Norway. Frequent co-authors include Stan G. Louie, Mark P. Okamoto, Alfred Chin, Paul M. Beringer, Bradley R. Williams, Jack W. Kern, Albert E. Yellin, David A. Sclar, Kazuhiro Inagaki and Peter N.R. Heseltine. Their work appears in journals such as American Journal of Health-System Pharmacy, Therapeutic Drug Monitoring, Antimicrobial Agents and Chemotherapy, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy and Annals of Pharmacotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.